A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
about
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohortsLung Cancer Gene Signatures and Clinical PerspectivesEnsemble-based network aggregation improves the accuracy of gene network reconstructionA network flow-based method to predict anticancer drug sensitivityPrediction of cancer proteins by integrating protein interaction, domain frequency, and domain interaction data using machine learning algorithms.Assessing the clinical utility of genomic expression data across human cancers.Strategies for power calculations in predictive biomarker studies in survival dataIntegrative Analysis of Gene Networks and Their Application to Lung Adenocarcinoma Studies.ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism.AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancerGene expression profile of A549 cells from tissue of 4D model predicts poor prognosis in lung cancer patientsA meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinomaCentromere and kinetochore gene misexpression predicts cancer patient survival and response to radiotherapy and chemotherapy.Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.The evolving genomic classification of lung cancer.Lysyl hydroxylase 2 induces a collagen cross-link switch in tumor stromaPrognostic markers in lung cancer: is it ready for prime time?Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinomaRibonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking statusPrediction of Clinical Outcome for All Stages and Multiple Cell Types of Non-small Cell Lung Cancer in Five Countries Using Lung Cancer Prognostic Index.Prognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal AdenocarcinomaIncreased Expression of TGFβR2 Is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients Treated with Chemotherapy.An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.Statistical completion of a partially identified graph with applications for the estimation of gene regulatory networksEnhanced construction of gene regulatory networks using hub gene informationThyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome.DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective.A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver MetastasesCell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.The expression profile and clinic significance of the SIX family in non-small cell lung cancerConsensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma.Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.An 8-gene signature for prediction of prognosis and chemoresponse in non-small cell lung cancer.Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples.Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies.Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests.Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
P2860
Q27345462-26E83F0A-9000-41B9-8C79-F5F5BF962AE5Q28383695-DD4CE5D4-ECFF-4B65-A613-1A331ED4A5CAQ28387769-C5CB4600-2B19-456D-B61E-285B4E0E1D58Q28544882-8D38AC47-56D2-430D-B860-59B3EF746AC3Q28547323-0A82DA41-B249-4FFD-9C10-F45B88727F57Q30930272-2E6282D3-C811-4098-AC3C-23D6FAD10787Q31109151-9D11F3AE-92DD-4109-B389-1630D7FB8DECQ31132692-2679C008-83CE-4694-9407-D9714008E20BQ33565864-2B411FAA-87C8-430B-8EDC-2E065FBB2715Q33685931-6DFCEA04-0A7F-451D-8E03-F4F48617DE57Q33750741-2A6A8CBE-28F4-4864-88FF-52B3C720A1F7Q33805831-D2C561B3-C6C5-4B79-A0AF-5B16EE3084D8Q33854958-061E4D00-E9C3-4AEA-90D0-8C5E1DA15B1EQ34538974-8E3F330E-95F1-4E39-A7D5-08F765B42910Q34743874-01C4F0B2-9DF8-4FDD-B9F5-7211E1DACBD8Q34852043-3F68C1E0-AB79-4A34-B316-C40FFAB13F01Q35183870-7C654B46-B5D0-4EF6-9268-627B1996085FQ35200555-9A4C0817-B8E2-41B3-A624-9F7AFFDC33E0Q35591891-4D33BB21-D1F5-4452-9615-F8CB389C23FCQ35637007-77C92855-17EE-4226-B8A1-6AF3C0E1A7A5Q35687989-8A68E390-F488-426F-914A-89F0DF790B43Q35738659-7A8153C6-E5B9-413A-A66D-ECE191CE1738Q35739691-90D53917-804F-40DE-AB27-8862F998D4AAQ35920986-9879C189-63BE-49D3-9BB1-9B0CA8F742E8Q36061682-2AE90FAE-60BD-48B7-B5A3-E4FAB127E661Q36320823-7B9AC1BF-2A36-4B89-840C-25D4634A52E8Q36615870-5A87DAA2-1AF0-4D6E-BC31-96AA8A671B71Q36956378-5D6EABC1-4EE1-431F-A020-C5AC8F2CED02Q37123982-0D3C7CBC-55B7-4622-9BF4-ECDDBD5E243FQ37163109-9F05CF08-7F7E-44C8-8F47-58F1A0D05D20Q37376521-91486047-EE37-4C03-9295-11D0C8FC5D57Q37400801-397D7E9F-E2CE-47D0-9575-BC875090425CQ37619692-0268143D-2834-4423-B915-D9EC2AF202DAQ37696112-1CF38993-4AFE-42C2-8E09-7B90C7B6A793Q37699284-D77AC6BA-8F65-413C-B048-359FA9368A14Q37701656-E41C26BB-1115-493E-AEA5-3142DFFB8377Q38218536-BDFF20EF-F259-4742-AA6B-239E683D701CQ38411881-C3B9DCC0-571C-4D7C-BD54-3EA5D4A84D53Q38432142-741B5428-4483-48BC-8E46-E67FA0B18634Q38688789-3E0A8F65-EB71-406F-9F71-A78960B9C7DF
P2860
A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A 12-gene set predicts surviva ...... all cell lung cancer patients.
@en
type
label
A 12-gene set predicts surviva ...... all cell lung cancer patients.
@en
prefLabel
A 12-gene set predicts surviva ...... all cell lung cancer patients.
@en
P2093
P2860
P1476
A 12-gene set predicts surviva ...... all cell lung cancer patients.
@en
P2093
Alejandro Corvalan
Carmen Behrens
Chi-Wan Chow
Guanghua Xiao
Jeffrey Allen
Joan Schiller
John D Minna
Michael A White
Milind Suraokar
P2860
P304
P356
10.1158/1078-0432.CCR-12-2321
P407
P577
2013-01-28T00:00:00Z